B A Berkowitz1, Y Ito, T S Kern, C McDonald, R Hawkins. 1. Department of Anatomy and Cell Biology, Kresge Eye Institute, Wayne State University, Detroit, Michigan 48201, USA. baberko@med.wayne.edu
Abstract
PURPOSE: To test the hypothesis that regional retinal oxygenation responses to a hyperoxic inhalation challenge are associated with reported retinopathy outcomes after different therapies in rat models of diabetic retinopathy. METHODS: Six groups of rats were maintained for 3 months: controls (n = 8), untreated diabetic (n = 8), aminoguanidine (AMG)-treated diabetic (2.5 g/kg of diet; n = 6), untreated galactosemic (n = 7), AMG-treated galactosemic (n = 10), and WAY-509-treated (25 mg/kg body weight per day) galactosemic (n = 7). After 3 months, the change in oxygen tension was measured noninvasively from the superior to the inferior ora serrata, using a novel functional magnetic resonance imaging (fMRI) technique and a carbogen (a gas mixture of 5% carbon dioxide and 95% oxygen that has been used clinically, instead of 100% oxygen, to minimize the vasoconstrictive effects of pure O(2) on retinal blood flow and oxygenation) inhalation challenge. Retinal morphometric measurements were also obtained. RESULTS: Retinal lesions (acellular capillaries and pericyte ghosts) were not significantly (P > 0.05) present at 3 months in any experimental groups compared with the control group. Superior but not inferior hemiretinal change in partial pressure of oxygen (DeltaPO(2)) became significantly subnormal (P < 0.05) at 3 months of diabetes or galactosemia. Aminoguanidine, which has been found to inhibit the development of retinopathy in diabetic but not galactosemic rats, inhibited the development of a subnormal DeltaPO(2) in diabetes but not in galactosemia. WAY-509, which has been reported to inhibit retinopathy in galactosemic rats, inhibited the DeltaPO(2) defect in galactosemic rats. CONCLUSIONS: An early subnormal superior hemiretinal DeltaPO(2) after treatment appears to be a good predictor of the risk of development of retinopathy, as well as for assessing therapeutic efficacy in experimental diabetic retinopathy.
PURPOSE: To test the hypothesis that regional retinal oxygenation responses to a hyperoxic inhalation challenge are associated with reported retinopathy outcomes after different therapies in rat models of diabetic retinopathy. METHODS: Six groups of rats were maintained for 3 months: controls (n = 8), untreated diabetic (n = 8), aminoguanidine (AMG)-treated diabetic (2.5 g/kg of diet; n = 6), untreated galactosemic (n = 7), AMG-treated galactosemic (n = 10), and WAY-509-treated (25 mg/kg body weight per day) galactosemic (n = 7). After 3 months, the change in oxygen tension was measured noninvasively from the superior to the inferior ora serrata, using a novel functional magnetic resonance imaging (fMRI) technique and a carbogen (a gas mixture of 5% carbon dioxide and 95% oxygen that has been used clinically, instead of 100% oxygen, to minimize the vasoconstrictive effects of pure O(2) on retinal blood flow and oxygenation) inhalation challenge. Retinal morphometric measurements were also obtained. RESULTS:Retinal lesions (acellular capillaries and pericyte ghosts) were not significantly (P > 0.05) present at 3 months in any experimental groups compared with the control group. Superior but not inferior hemiretinal change in partial pressure of oxygen (DeltaPO(2)) became significantly subnormal (P < 0.05) at 3 months of diabetes or galactosemia. Aminoguanidine, which has been found to inhibit the development of retinopathy in diabetic but not galactosemicrats, inhibited the development of a subnormal DeltaPO(2) in diabetes but not in galactosemia. WAY-509, which has been reported to inhibit retinopathy in galactosemicrats, inhibited the DeltaPO(2) defect in galactosemicrats. CONCLUSIONS: An early subnormal superior hemiretinal DeltaPO(2) after treatment appears to be a good predictor of the risk of development of retinopathy, as well as for assessing therapeutic efficacy in experimental diabetic retinopathy.
Authors: Roselie M H Diederen; Catherine A Starnes; Bruce A Berkowitz; Barry S Winkler Journal: Invest Ophthalmol Vis Sci Date: 2006-06 Impact factor: 4.799
Authors: Bruce A Berkowitz; Marius Gradianu; Stephen Schafer; Ying Jin; Andre Porchia; Raymond Iezzi; Robin Roberts Journal: Invest Ophthalmol Vis Sci Date: 2008-03-24 Impact factor: 4.799
Authors: Rod D Braun; Marius Gradianu; Kerry S Vistisen; Robin L Roberts; Bruce A Berkowitz Journal: Invest Ophthalmol Vis Sci Date: 2007-03 Impact factor: 4.799
Authors: Bruce A Berkowitz; Robin Roberts; Hongmei Luan; David Bissig; Bang V Bui; Marius Gradianu; David J Calkins; Algis J Vingrys Journal: Invest Ophthalmol Vis Sci Date: 2007-08 Impact factor: 4.799
Authors: Bruce A Berkowitz; Robin Roberts; Deanna A Oleske; Myungwon Chang; Stephen Schafer; David Bissig; Marius Gradianu Journal: Invest Ophthalmol Vis Sci Date: 2008-12-05 Impact factor: 4.799